Evidence map›Paper›PMID 36179121›Full record

ArticleThe journal of applied laboratory medicine2022

Sensitive Serology Measurements in the Saliva of Individuals with COVID-19 Symptoms Using a Multiplexed Immunoassay.

Dorsa Sohaei, Antigona Ulndreaj, Anu Mathew, Christopher Campbell, Martin Stengelin, George Sigal, Jessica Joe, Daniel Romero, Nikhil Padmanabhan, Annie Ren and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of applied laboratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. The Seraph 100Antibodies (Basel, Switzerland) · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Dorsa SohaeiDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Antigona UlndreajLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Anu MathewMeso Scale Diagnostics, LLC, Rockville, MD, USA.ORCID 0000-0003-3327-3083
Christopher CampbellMeso Scale Diagnostics, LLC, Rockville, MD, USA.
Martin StengelinMeso Scale Diagnostics, LLC, Rockville, MD, USA.
George SigalMeso Scale Diagnostics, LLC, Rockville, MD, USA.ORCID 0000-0001-7149-6400
Jessica JoeMeso Scale Diagnostics, LLC, Rockville, MD, USA.
Daniel RomeroMeso Scale Diagnostics, LLC, Rockville, MD, USA.
Nikhil PadmanabhanMeso Scale Diagnostics, LLC, Rockville, MD, USA.
Annie RenDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Atefeh GhorbaniDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Antoninus SoosaipillaiDepartment of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.
Vathany KulasingamDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Ioannis PrassasLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Eleftherios P DiamandisDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-1589-820X
Meso Scale Discovery (United States) · USMount Sinai Hospital · CAUniversity Health Network · CAUniversity of Toronto · CA

Funding

NIAID NIH HHS HHSN272201700013C
6 · The paper itself

Abstract

backgroundThere are numerous benefits to performing salivary serology measurements for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen for coronavirus disease 2019 (COVID-19). Here, we used a sensitive multiplex serology assay to quantitate salivary IgG against 4 SARS-CoV-2 antigens: nucleocapsid, receptor-binding domain, spike, and N-terminal domain.

methodsWe used single samples from 90 individuals with COVID-19 diagnosis collected at 0 to 42 days postsymptom onset (PSO) and from 15 uninfected control subjects. The infected individuals were segmented in 4 groups (0-7 days, 8-14 days, 15-21 days, and >21 days) based on days PSO, and values were compared to controls.

resultsCompared to controls, infected individuals showed higher levels of antibodies against all antigens starting from 8 days PSO. When applying cut-offs with at least 93.3% specificity at every time interval segment, nucleocapsid protein serology had the best sensitivity at 0 to 7 days PSO (60% sensitivity [35.75% to 80.18%], ROC area under the curve [AUC] = 0.73, P = 0.034). Receptor-binding domain serology had the best sensitivity at 8 to 14 days PSO (83.33% sensitivity [66.44%-92.66%], ROC AUC = 0.90, P < 0.0001), and all assays except for N-terminal domain had 92% sensitivity (75.03%-98.58%) at >14 days PSO.

conclusionsThis study shows that our multiplexed immunoassay can distinguish infected from uninfected individuals and reliably (93.3% specificity) detect seroconversion (in 60% of infected individuals) as early as the first week PSO, using easy-to-collect saliva samples.

Indexed as

COVID-19Antibodies, ViralCOVID-19 TestingHumansImmunoassayImmunoglobulin GSalivaSARS-CoV-2Sensitivity and SpecificitySpike Glycoprotein, CoronavirusAntibodies, ViralImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID36179121
PMCPMC9619505
OpenAlexW4298111073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.